This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Usmani, Saad
Item Type | Name |
Concept
|
Thalidomide
|
Academic Article
|
Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
|
Academic Article
|
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
|
Academic Article
|
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
|
Academic Article
|
Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1.
|
Academic Article
|
Thalidomide and its analogues in the treatment of Multiple Myeloma.
|
Academic Article
|
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
|
Academic Article
|
Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.
|
Academic Article
|
How long can we let the myeloma smolder?
|
Academic Article
|
Novel drug combinations for the management of relapsed/refractory multiple myeloma.
|
Academic Article
|
Maintenance lenalidomide after transplantation: How much is enough?
|
Academic Article
|
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
|
Academic Article
|
Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma.
|
Academic Article
|
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
|
Academic Article
|
Practical Considerations in Managing Relapsed Multiple Myeloma.
|
Academic Article
|
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.
|
Academic Article
|
Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
|
Academic Article
|
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
|
Academic Article
|
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.
|
Academic Article
|
Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
|
Academic Article
|
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
|
Academic Article
|
Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse.
|
Academic Article
|
Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4.
|